From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

Abstract:

:Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise review article, we will summarize the application of antibodies designed to target antigens expressed by tumor cells, and the transition from these antibodies to the generation of CARs.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Caruana I,Diaconu I,Dotti G

doi

10.1053/j.seminoncol.2014.08.005

subject

Has Abstract

pub_date

2014-10-01 00:00:00

pages

661-6

issue

5

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(14)00179-1

journal_volume

41

pub_type

杂志文章,评审
  • Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

    abstract::Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissio...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.08.011

    authors: Mills GB,Kohn E,Lu Y,Eder A,Fang X,Wang H,Bast RC,Gray J,Jaffe R,Hortobagyi G

    更新日期:2003-10-01 00:00:00

  • Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy.

    abstract::This ongoing study was initiated to determine the feasibility of administering amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD) with monomodal high-dose rate (mHDR) brachytherapy and to assess the tolerability and side effects of this combination. To date, 18 patients suitable for prostate implant brachy...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.010

    authors: Dziuk T,Senzer N

    更新日期:2003-12-01 00:00:00

  • Pharmacogenetics in esophageal cancer.

    abstract::The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics. This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.04.031

    authors: Wu X,Lu C,Chiang SS,Ajani JA

    更新日期:2005-12-01 00:00:00

  • Epigenetics meets immune checkpoints.

    abstract::Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availab...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.02.003

    authors: Covre A,Coral S,Di Giacomo AM,Taverna P,Azab M,Maio M

    更新日期:2015-06-01 00:00:00

  • Small cell carcinoma of the head and neck: a review.

    abstract::Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck. Excluding cases that are considered to arise from skin, SCC in the head and neck has been found to develop in nearly all structures associated wit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.10.024

    authors: Renner G

    更新日期:2007-02-01 00:00:00

  • Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.

    abstract::Relapse following complete remission achieved with a single course of high-dose chemotherapy continues to be the main cause of treatment failure in patients with metastatic breast cancer. A phase I/II trial was initiated that combined the two most active drugs against breast cancer, doxorubicin and paclitaxel (Taxol; ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rahman Z,Champlin R,Rondon G,Frye D,Valero V,Mehra R,Hortobagyi G

    更新日期:1997-10-01 00:00:00

  • Treatment of brain metastases of small cell lung cancer with teniposide.

    abstract::Over 50% of patients with small cell lung cancer (SCLC) will develop symptomatic brain metastases during the course of their disease. Results of whole brain radiotherapy, the standard treatment, are rather poor and relapses are frequent. Thus, new modes of therapy are urgently needed for these patients. In this study,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Postmus PE,Smit EF,Berendsen HH,Sleijfer DT,Haaxma-Reiche H

    更新日期:1992-04-01 00:00:00

  • Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.

    abstract::We report the updated results of an intensive treatment protocol for children (< 18 years) and adults (> or = 18 years) with advanced B-cell lymphomas. The protocol consists of two chemotherapy regimens: A, consisting of cyclophosphamide, doxorubicin, vincristine and high-dose methotrexate (CODOX-M), and B, consisting...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Adde M,Shad A,Venzon D,Arndt C,Gootenberg J,Neely J,Nieder M,Owen W,Seibel N,Wilson W,Horak ID,Magrath I

    更新日期:1998-04-01 00:00:00

  • Opportunities and challenges in the development of targeted therapies.

    abstract::Expanding knowledge about basic biology and a detailed understanding of the signaling pathways that participate in the growth and metastasis of breast cancer have identified opportunities for diagnostic and therapeutic intervention. Endocrine therapy represents the first and most successful example of targeted therapy...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.01.003

    authors: Hortobagyi GN

    更新日期:2004-02-01 00:00:00

  • Interferons and their stimulated genes in the tumor microenvironment.

    abstract::Constitutive expression of interferons (IFNs) and activation of their signaling pathways have pivotal roles in host responses to malignant cells in the tumor microenvironment. IFNs are induced by the innate immune system and in tumors through stimulation of Toll-like receptors (TLRs) and through other signaling pathwa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.02.002

    authors: Cheon H,Borden EC,Stark GR

    更新日期:2014-04-01 00:00:00

  • Monoclonal antibody treatment of solid tumors: a coming of age.

    abstract::Over the past 5 years there has been a renewed interest in the use of monoclonal antibodies and immunoconjugates in the treatment of nonhematologic malignancies. This enthusiasm has stemmed from advances in recombinant technology allowing for the production of chimeric and humanized antibodies, from Food and Drug Admi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Murray JL

    更新日期:2000-12-01 00:00:00

  • Intrahepatic arterial infusion of chemotherapy: clinical results.

    abstract::Approximately 60% of patients diagnosed with colorectal cancer (CRC) will go on to develop hepatic metastases. Although surgical resection is the only curative modality, a majority will not be able to undergo surgery. Alternative methods for treating this population have focused on the feasibility of hepatic arterial ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31680

    authors: Dizon DS,Kemeny NE

    更新日期:2002-04-01 00:00:00

  • Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study.

    abstract::The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when combined with standard, curative-intent radiation t...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rosenthal DI,Okani O,Corak J,Kavanaugh D,Kamen B,Vuitch FM,Gazdar AF,Greiner J,Frenkel EF,Carbone DP

    更新日期:1997-08-01 00:00:00

  • A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.

    abstract::This phase I study was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) with standard doses of cisplatin and etoposide for patients with untreated, extensive-stage small cell lung cancer. Secondary objectives were to determine the toxicities, response ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bunn PA Jr,Kelly K

    更新日期:1997-08-01 00:00:00

  • The Bayesian basket design for genomic variant-driven phase II trials.

    abstract::Basket clinical trials are a new category of early clinical trials in which a treatment is evaluated in a population of patients with tumors of various histologic types and primary sites selected for containing specific genomic abnormalities. The objective of such studies is generally to discover histologic types in w...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2016.01.002

    authors: Simon R,Geyer S,Subramanian J,Roychowdhury S

    更新日期:2016-02-01 00:00:00

  • Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.

    abstract::The optimal management of early stage ovarian cancer with poor prognostic features remains controversial. On the basis of results of studies in advanced ovarian cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in combination with a platinum agent has become part of adjuvant chemotherapy trials i...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Young RC

    更新日期:2000-06-01 00:00:00

  • Factors influencing quality of life in cancer patients: anemia and fatigue.

    abstract::Anemia is a multi-symptom syndrome involving both physical and emotional problems that can be evaluated for their impact on quality of life. Fatigue is the cardinal symptom of anemia, reported by three of four cancer patients using the general version of the Functional Assessment of Cancer Therapy (FACT-G) questionnai...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Cella D

    更新日期:1998-06-01 00:00:00

  • Treatment of cancer-related hypercalcemia.

    abstract::Hypercalcemia, a complication that develops in 10% to 20% of patients with cancer, results from disruption of the normal physiologic mechanisms that closely regulate calcium homeostasis. Most patients with hypercalcemia are seriously dehydrated, and this volume depletion further compromises the kidney's ability to exc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Ritch PS

    更新日期:1990-04-01 00:00:00

  • A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.

    abstract::This randomized, multinational, multicenter study was designed to determine the response rate of gemcitabine monotherapy and cisplatin/etoposide combination therapy in chemotherapy-naive patients with advanced, recurrent, and/or metastatic non-small cell lung cancer (stage IIIA [if inoperable], IIIB, or IV). One group...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Manegold C,Drings P,von Pawel J,Ricci S,Dornoff W,van Walree N,ten Bokkel Huinink W,Chemaissani A,Stahel P,Bergman B,Wagenius G,Sederholm C,Mattson K,Liippo K,Kellokumpu-Lehtinen P

    更新日期:1997-06-01 00:00:00

  • Vascular toxicity of antineoplastic agents.

    abstract::Among the various deleterious effects of cancer chemotherapy, vascular toxicity is the least well recognized. This lack of recognition may be because the vasculotoxic phenomena are not unique to antineoplastic agents, can occur in patients without exposure to these agents, and the fact cancer itself may produce a hype...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.11.006

    authors: Shahab N,Haider S,Doll DC

    更新日期:2006-02-01 00:00:00

  • Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).

    abstract::We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. Patients who did not require therapy for more than 1 year (n = 54) could be distinguis...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/sonc.2003.50050

    authors: Dhodapkar MV,Jacobson JL,Gertz MA,Crowley JJ,Barlogie B

    更新日期:2003-04-01 00:00:00

  • 3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.

    abstract::Early detection of response to neoadjuvant chemoradiation in esophageal cancer may allow individualization of treatment strategies and avoidance of unnecessary treatment. Although positron emission tomography (PET) with [(18)F]fluorodeoxyglucose (FDG) permits detection of changes in tumor proliferation before any chan...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.01.002

    authors: Chao KS

    更新日期:2007-04-01 00:00:00

  • THe genetics of familial breast cancer.

    abstract::Because studies of breast cancer patients and their relatives provide statistical evidence for involvement of autosomal dominant genes, the identification of specific genetic effects has long been the focus of efforts to identify women at exceedingly high risk. BRCA1, a gene that confers greatly increased susceptibili...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Cannon-Albright LA,Skolnick MH

    更新日期:1996-02-01 00:00:00

  • Immunotherapy of cancer with genetically modified tumor vaccines.

    abstract::Distant metastasis is the major cause for therapeutic failures in Clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease....

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Gilboa E

    更新日期:1996-02-01 00:00:00

  • Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment.

    abstract::Long-term survival is occasionally observed in patients with neoplastic meningitis (NM) accompanying breast cancer (13% one-year and 6% 2-year survival), melanoma, and lymphoma, but in general the survival of most patients is short and averages only 3 to 4 months. The incidence of NM appears to be increasing, in part ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.04.016

    authors: Jaeckle KA

    更新日期:2006-06-01 00:00:00

  • Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.

    abstract::Phase I trials of the intraperitoneal (IP) administration of cisplatin have demonstrated that the drug can be safely delivered by this route with a major increase in exposure (approximately tenfold to 15-fold) of the cavity to the cytotoxic agent compared with that of the systemic circulation. Phase I trials of IP cis...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Markman M

    更新日期:1989-08-01 00:00:00

  • Photodynamic therapy for lung cancer and malignant pleural mesothelioma.

    abstract::Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen ((1)O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. PDT is increasingly being used to treat thoracic mali...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.09.017

    authors: Simone CB 2nd,Cengel KA

    更新日期:2014-12-01 00:00:00

  • Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team.

    abstract::In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung ca...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Pisters KM,Kris MG,Bunn PA Jr,Johnson DH,Ruckdeschel JC,Crowley JJ,Ginsberg RJ

    更新日期:1997-08-01 00:00:00

  • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.

    abstract::The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2017.08.004

    authors: Capoluongo E,Ellison G,López-Guerrero JA,Penault-Llorca F,Ligtenberg MJL,Banerjee S,Singer C,Friedman E,Markiefka B,Schirmacher P,Büttner R,van Asperen CJ,Ray-Coquard I,Endris V,Kamel-Reid S,Percival N,Bryce J,Röthlisbe

    更新日期:2017-06-01 00:00:00

  • Roadmap for new opportunities in melanoma research.

    abstract::Investigators representing all major melanoma research areas present an overview of the most important challenges for the field. Four major research areas are covered plus the training of new investigators. For each area we first describe the present status, its strengths and weaknesses, and then outline specific reco...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.09.004

    authors: Herlyn M,Halaban R,Ronai Z,Schuchter L,Berwick M,Pinkel D

    更新日期:2007-12-01 00:00:00